Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments
PAT after MI is Rs. 41 crore which is 162% increase
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024
The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence
The special financing terms offered by United Imaging and structured by Medikabazaar to Krsnaa Diagnostics underscore the strategic importance of this alliance
Subscribe To Our Newsletter & Stay Updated